US FDA Punts To Congress On CBD: Rx Topics Remain Outside Political Spotlight

FDA is formally asking Congress to weigh in on the best approach to regulate CBD in consumer products. That provides another target for legislative attention that may mean that FDA’s core drug regulatory activities stay comfortably out of the spotlight.